Congressional Budget Office Cost Estimate: H.R. 5668, Making Objective Drug Evidence Revisions for New Labeling Act of 2020 [open pdf - 34KB]
This is the Congressional Budget Office Cost Estimate as ordered reported by the House Committee on Energy and Commerce on July 15, 2020. From the Document: "Under current law, labels on generic drugs must match those of their corresponding reference brand drug. H.R. 5668 would allow the Secretary of Health and Human Services to require label updates for certain generic drugs once the reference drug's patents and exclusivities expire, new information is available, and the Secretary determines that the public health would benefit from the updated label. The bill also would require the Secretary to report to the Congress every four years on the number and types of such determinations made and on the number of times manufacturers disagreed with those determinations."
Congressional Budget Office: https://www.cbo.gov/